Gankyrin, a recently discovered oncoprotein, is a promising target for drug therapy because it is overexpressed in most hepatocellular carcinomas. Since gankyrin interacts with MAGE-A4, we made several MAGE-A4 mutants and assessed their effects on cell growth. We found that the C-terminal 107 amino acids of MAGE-A4 (MAGE-A4⌬N1) induced p53-dependent and p53-independent apoptosis. MAGE-A4⌬N1 increased the p53 protein level, but decreased the p21
expressed in various forms of cancer, but not in most healthy adult tissues except for the testis (2) . MAGE genes encode tumor-specific antigenic peptides presented by HLA class I molecules to CD8 ϩ T lymphocytes (3) , and have therefore been extensively studied as targets for cancer immunotherapy (4, 5) . Despite recent reports that some members of the MAGE family play important roles in cell cycle control and apoptosis (6) , the physiological functions of MAGE proteins remain mostly unknown.
Hepatocellular carcinoma (HCC), one of the most common cancers in the world, develops from transformed hepatocytes during the course of chronic liver diseases (7) . When transformed hepatocytes expand in vivo, they encounter various microenvironmental stresses, such as hypoxia, decreased growth factor availability, and lack of nutrient supply, all of which activate apoptosis (8, 9) . In addition, activated oncogenes also trigger apoptosis (10) . Therefore, resistance to apoptosis is one of the essential alterations for development of HCCs.
Gankyrin (also known as PSMD10 and p28) is an oncoprotein overexpressed in most HCCs (11) . Gankyrin consists of seven ankyrin repeats (12) , and binds to the retinoblastoma tumor suppressor protein (RB), the S6 ATPase subunit of the 26 S proteasome, and cyclin-dependent kinase 4 (Cdk4) (11, 13) . Overexpression of gankyrin increases degradation of RB in vitro and in vivo, and oncogenically transforms NIH/3T3 cells (11) . Gankyrin binds to Cdk4 and counteracts the inhibitory function of the tumor suppressors p16INK4A and p18INK4C (14) . In a rodent model of hepatocarcinogenesis, gankyrin is overexpressed from the earliest stage of tumor development (15) . These findings suggest that gankyrin is a major player in cell cycle control and tumorigenesis in HCCs.
The POZ domain/zinc finger transcription factor Miz-1 binds to the core promoter of the Cdk inhibitor p21
Cip1 gene (16, 17) .
Although the p21
Cip1 promoter is highly responsive to p53, both p53 and Miz-1 are necessary for up-regulation of p21 Cip1 and cell cycle arrest upon UV irradiation (18) . Activation of p53 induces either cell cycle arrest mediated by transcriptional activation of p21
Cip1 or apoptotic cell death (9, 19) . The transactivation activity of Miz-1 has been shown to be inhibited by interaction with Myc (17, 20) , and the recruitment of Myc to the p21
Cip1 promoter by Miz-1 results in repression of p21
Cip1 transcription, even in the presence of activated p53 (21) . Thus, Myc switches the p53-dependent response of cells from cell cycle arrest to apoptosis. Previously, we have found that MAGE-A4 specifically interacts with gankyrin and suppresses its tumorigenic activity (22) . In this study, to further characterize the antitumorigenic activity of MAGE-A4 and to facilitate development of a therapeutic approach against HCCs, we made several mutants of MAGE-A4 and analyzed their effects on cell growth. We found that a C-terminal fragment of MAGE-A4 has strong pro-apo-ptotic activity, at least partly, by binding to Miz-1, and that a similar fragment is generated from full-length MAGE-A4 in human cells.
MATERIALS AND METHODS
Plasmids-Wild-type MAGE-A4 cDNA and mutant derivatives tagged with HA or FLAG cDNA, and gankyrin cDNA and Miz-1 cDNA tagged with HA cDNA were cloned into the eukaryotic expression vector pMKit-neo as previously described (11, 22) . Point mutations were introduced into plasmid DNA by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The bicistronic pIREShrGFP-1a vector (Stratagene) was used to express human p53, MAGE-A4 and MAGE-A4 mutants together with GFP. The pact-p53 plasmid expressing human wild-type p53 was kindly provided by Dr. S. Ishii, Tsukuba, Japan. A cDNA encoding 6 N-terminal histidines and the 11-amino acid protein transduction domain from the HIV tat protein (YGRKKRRQRRR) (23) was fused with a cDNA encoding the fulllength, N-terminal 210 or C-terminal 107 amino acids of MAGE-A4 in the pTAT vector (kindly provided by Dr. Steven F. Dowdy, La Jolla, CA).
Cell Culture-Mouse NIH/3T3 cells and derivative GK-S25 cells overexpressing gankyrin, human U-2 OS cells, HuH-7 cells, PLC/PRF/5 cells, H1299 cells, HeLa cells, 293T cells, and monkey COS-7 cells were cultured and transfected with plasmid DNAs as described (22) . For some experiments, cells were treated with the following chemicals (Calbiochem, San Diego, CA) or vehicle alone: adriamycin (0.1 and 1.0 M), Z-VAD-FMK (20 and 50 M), Ac-LDESD-CHO (50 M), Z-SEVD-FMK (50 M), and Z-LEHD-FMK (50 M). The numbers of surviving cells were counted by the trypan blue dye exclusion method using a hemocytometer under a microscope. To assess the anchorage dependence of growth in vitro, 5 ϫ 10 2 cells were incubated with recombinant proteins and assayed as previously described (22) . Statistical differences between sample means were calculated by analysis of variance, followed by the unpaired Student's t test.
Western Blot Analysis, Immunoprecipitation, and Northern Blot Analysis-Western blot analysis and immunoprecipitation were performed as described (11, 24) . Mouse monoclonal antibodies were anti-HA antibody (Roche Applied Science), anti-FLAG antibody (Sigma Aldrich, Tokyo, Japan), anti-SC35 antibody (Sigma Aldrich), anti-␣-tubulin antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-p53 antibody (BD Pharmingen, San Diego, CA), anti-His antibody (BD Biosciences Clontech, Palo Alto, CA), and anti-Bcl-xL antibodies (Santa Cruz Biotechnology, and BD Transduction Laboratories, Lexin, KY). Polyclonal antibodies were mouse anti-Miz-1 antibody (Santa Cruz Biotechnology), rabbit anti-␤-actin antibody (Chemicon International, Inc., Temecula, CA), and horseradish peroxidase-conjugated goat antimouse antibody (DAKO, Kyoto, Japan) and anti-rabbit antibody (DAKO). Interaction of transiently expressed exogenous MAGE-A4 or its mutants with exogenous Miz-1 was examined by co-transfecting COS-7 or HeLa cells with plasmids expressing FLAG-tagged MAGE-A4 or MAGE-A4⌬N1, FLAG alone, HA-tagged Miz-1, or HA alone in various combinations. Preparation of nuclear and cytoplasmic extracts and Northern blot analysis were performed as described (24) .
Measurement of Cellular DNA Content-Cells were harvested with 4 mM EDTA/PBS, fixed in 70% ethanol and stained with 5 g/ml propidium iodide (PI, Sigma Aldrich). The DNA content of the cells was analyzed with a flow cytometer (EPICS XL; Beckmann Coulter, Tokyo, Japan). To selectively analyze cells expressing transfected cDNA, only cells manifesting a high level of GFP fluorescence was analyzed.
TUNEL Assay-U-2 OS cells and HuH-7 cells were transfected with cDNAs encoding the C-terminal 107 amino acids of MAGE-A4 in the expression vector or vector alone using LipofectAmine Plus (Invitrogen, Carlsbad, CA). 36 h after transfection, the cells were rinsed three times with PBS and were fixed with 2% paraformaldehyde. The cells were then labeled by the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) reaction using the In Situ Cell Death Detection kit (Roche Applied Science). The same field of cells was examined under a confocal laser microscope (Olympus, Tokyo, Japan) for 4Ј, 6Ј-diamidino-2-phenylindole (DAPI) (Sigma Aldrich) staining and immunofluorescence.
Measurement of Caspase Activities-Approximately 4 ϫ 10 5 cells were used for measurement of caspase activities. Caspase-8-and caspase-9-like activities were measured using IETD-p-nitroanilide (MBL, Nagoya, Japan) and LEHD-p-nitroanilide (MBL) as substrates, respectively. The fluorescence of the released p-nitroanilide was measured at an excitation wavelength of 360 nm and an emission wavelength of 530 nm.
Measurement of Mitochondrial Membrane
Potential-To assess mitochondrial membrane potential, H1299 cells were transfected with plasmids expressing MAGE-A4⌬N1-IRES-hrGFP or vector alone. 48 h after transfection, cells were incubated in the medium containing 500 nM of MitoTracker Red CMXRos (Molecular Probes, Inc., Eugene, OR) for 30 min at 37°C. They were then trypsinized and resuspended in PBS. The red X-rosamine fluorescence of the GFP-positive cells was analyzed by flow cytometry.
Immunofluorescence Staining-Immunofluorescence staining was performed using mouse monoclonal anti-FLAG antibody (Sigma Aldrich), rabbit polyclonal anti-HA antibody (Berkeley Antibody, Richmond, CA) or anti-cytochrome c antibody (Santa Cruz Biotechnology) as described previously (24) . The bound antibodies were reacted with FITC-linked antimouse and TRITC-linked anti-rabbit IgGs (Amersham Biosciences) and observed under a confocal laser microscope (Olympus).
Yeast Two-hybrid Assay-Using the C-terminal 107 amino acids of MAGE-A4 as bait, a U-2 OS cell cDNA library was screened by the yeast two-hybrid method as described (22) .
Gel Shift Experiments-COS-7 cells were transfected with plasmids expressing HA-tagged Miz-1 and FLAG-tagged MAGE-A4⌬N1, and nuclear extracts were prepared as described (24) . Binding was carried out for 10 min at room temperature in 20 mM HEPES pH 7.8, 5 mM MgCl 2 , 5 mM KCl, 0.5% Nonidet P-40, 500 mM NaCl, 0.1% deoxycholate, and protease inhibitors. 32 P-labeled oligonucleotides spanning the site of the human p21
Cip1 gene (Ϫ46 to Ϫ32) was used as a probe (21) . Reporter Assays-Luciferase reporter plasmids containing the Ϫ518 to ϩ32 region of the p21
Cip1 gene as a promoter were co-transfected with pRL-TK (Promega, Madison, WI) and increasing amounts of plasmids expressing MAGE-A4⌬N1 onto HeLa cells by the calcium phosphate method. After 30 h, cells were lysed and luciferase activity was measured by the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer's protocol.
Preparation of Wild-type MAGE-A4 and Mutants Fused to HIV Tat Protein-The
His-tagged Tat-fused proteins were expressed in and purified from BL21(DE3)pLysS cells (Novagen, Darmstadt, Germany) as described (23) . BL21(DE3)pLysS cells from overnight culture were spun down and then sonicated in buffer Z (8 M urea, 100 mM NaCl, 20 mM Hepes, pH 8.0). The supernatant of the centrifuged sonicate was loaded onto an Econocolumn (Bio-Rad Laboratories, Hercules, CA) packed with a 3-ml Ni-NTA column (Qiagen, Tokyo, Japan). Eluted proteins were then desalted on a PD-10 column (Amersham Biosciences, Piscataway, NJ) in PBS, aliquoted, and flash frozen in 10% glycerol, and stored at Ϫ80°C. Bovine serum albumin passed through a PD-10 column in PBS was used as a control.
Tumorigenicity in Nude Mice-12 female BALB/c Slc-nu/nu athymic mice (4 weeks old) were injected s.c with GK-S25 cells (8 ϫ 10 6 cells each) suspended in PBS. The cells were pre-incubated either with 500 nM Tat-MAGE-A4⌬N1 or bovine serum albumin (six mice each) in PBS for 60 min, washed in PBS, and then injected. Tumor size was calculated by measuring the length, width, and thickness with calipers. This work was carried out under the Japanese Law Concerning the Care and Control of Animals, and has been approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University.
RESULTS

Pro-apoptotic Activity of N-terminally Truncated MAGE-A4 -MAGE-A4
directly interacts with gankyrin and suppresses its tumorigenic activity, although it shows no effect on cell cycle progression or apoptosis (22) . While investigating the effects of MAGE-A4 and its deletion mutants on cell growth, we noticed that a C-terminal fragment of MAGE-A4 (residues 211-317, MAGE-A4⌬N1) induced cell death (Fig. 1A) . At 48 h after transfection, about 25% of U-2 OS cells expressing MAGE-A4⌬N1 together with GFP were positively stained with PI. The effect was comparable to that of p53. As expected, the percentage of PI-positive cells expressing GFP and full-length MAGE-A4 (residues 1-317) or the N terminus of MAGE-A4 (residues 1-210) were not different from that expressing GFP alone (Fig. 1A) .
To assess whether MAGE-A4⌬N1 induced cell death by apoptosis, we measured the DNA content of cells by flow cytometry. As shown in Fig. 1B , a significant increase in the percentage of cells with sub-G 1 DNA content was observed in U-2 OS cells expressing MAGE-A4⌬N1 compared with those express-ing full-length or N terminus of MAGE-A4 or GFP alone. The kinetics of the change in the DNA content of cells expressing MAGE-A4⌬N1 was similar to that induced by p53 (Fig. 1C) . At 45 and 60 h after transfection, 20 -25 and 55-60%, respectively, of transfectants showed sub-G 1 DNA content. Essentially similar results were obtained when MAGE-A4⌬N1 was expressed together with GFP in HuH-7 hepatoma cells (data not shown).
We next examined the pro-apoptotic activities of the C termini of other MAGE-A family proteins structurally similar to MAGE-A4, i.e. MAGE-A1, MAGE-A2, and MAGE-A12 (1) in U2-OS cells. As shown in Fig. 1D , MAGE-A4⌬N1 showed the strongest pro-apoptotic activity among MAGE-A family members studied.
When we performed TUNEL staining of HuH-7 cells after transfection with plasmids expressing MAGE-A4⌬N1, TUNEL positive HuH-7 cells displayed chromatin condensation (Fig.  1E) . Significantly, more HuH-7 cells expressing MAGE-A4⌬N1 were TUNEL positive compared with those transfected with the empty vector (Fig. 1F ). Taken together, these results demonstrated that MAGE-A4⌬N1 induces apoptosis in human cancer cells, while full-length MAGE-A4 does not.
The apoptosis-inducing effects of various MAGE-A4 mutants were next examined by selectively analyzing U-2 OS transfectants bicistronically expressing GFP. As shown in Fig. 2 , MAGE-A4⌬N1 induced apoptosis as efficiently as p53. Further deletion of N-terminal or C-terminal amino acids from MAGE-A4⌬N1 decreased its pro-apoptotic activity, indicating that both N-terminal (residues 211-226) and C-terminal (residues 288 -317) amino acids were essential for maximal activity.
Induction of p53-dependent and p53-independent Apoptosis by MAGE-A4⌬N1-Most apoptotic mechanisms are dependent on caspase activities (25) . The broad range caspase inhibitor Z-VAD-FMK prevented apoptosis induced by MAGE-A4⌬N1 in U-2 OS cells (Fig. 3A) . Two caspase-activating pathways that lead to apoptosis are well characterized, i.e. the caspase-8-activating pathway and the caspase-9-activating pathway (8, 25, 26) . The former is initiated from cell surface death receptors, while the latter is triggered by various stress signals and involves changes in mitochondrial integrity. A significant increase in caspase-9 activity, but not caspase-8 activity, was detected in U-2 OS cells expressing MAGE-A4⌬N1 (Fig. 3B) .
Within the mitochondrial apoptotic pathway, the ratio of Bcl-2 family death agonists to antagonists dictates the susceptibility of cells to an apoptotic stimulus (27) . Bcl-xL and Bcl-2 works as death antagonists either by preventing the release of mitochondrial caspase-activating factors such as cytochrome c or by sequestration and inhibition of caspases via interaction with APAF-1 (apoptotic protease-activating factor-1) (8, 26, 28 ). When we examined the level of Bcl-2 family members in U-2 OS cells overexpressing MAGE-A4⌬N1, a decrease in the level of Bcl-xL, but no change in the levels of other Bcl-2 family members including Bax and Bid were observed ( Fig. 3C and data not shown).
The tumor suppressor p53 induces mitochondria-mediated apoptosis in many experimental systems and increases caspase-9 activity (9). Thus, we examined whether p53 is involved in MAGE-A4⌬N1-induced apoptosis. We first determined the levels of p53 in U-2 OS cells after transfection with cDNAs expressing MAGE-A4 or its various mutants (Fig. 3D) . Plasmids expressing luciferase were co-transfected as a control for transfection efficiency. An increase in the p53 protein level was observed in MAGE-A4⌬N1 transfectants. MAGE-A4⌬N1⌬C2 and MAGE-A4⌬N1⌬C3, which showed pro-apoptotic activities (Fig. 2B ) also increased p53 levels. These findings are consistent with the notion that p53 is involved in the MAGE-A4⌬N1-induced apoptosis. p21
Cip1 is known to protect cells from p53-induced cell death in addition to inhibiting cell proliferation (20, 29) . As shown in Fig. 3E , MAGE-A4⌬N1 decreased the levels of p21
Cip1 transcript and protein. Taken together, these results strongly suggest that MAGE-A4⌬N1 induces apoptosis in a p53-dependent manner. However, despite low p53 levels apoptosis was observed in MAGE-A4⌬N2 and MAGE-A4⌬N3 transfectants (Figs. 2B and 3D). Furthermore, MAGE-A4⌬N1 showed more potent proapoptotic activity than that expected from the up-regulated level of p53 (Fig. 4A) . These results suggest that some of the observed pro-apoptotic activities of MAGE-A4⌬N1 are p53-independent. To assess this possibility, we examined the sensitivity of p53-defective cells, i.e. HuH-7 and PLC/PRF/5 hepatoma cell lines containing mutant p53 (30) and H1299 lung cancer cell line deficient in p53 (31) to MAGE-A4⌬N1-induced apoptosis. As shown in Fig. 4B , MAGE-A4⌬N1 induced apoptosis in the absence of wild-type p53. The p53-independent MAGE-A4⌬N1-induced apoptosis was also dependent on a caspase(s) (Fig. 4C) , and was accompanied by increased caspase-9, but not caspase-8, activity (Fig. 4D) . In H1299 cells, expression of MAGE-A4⌬N1 disrupted mitochondrial integrity (Fig. 4E) , and induced release of cytochrome c from mitochondria (Fig. 4F) . These results indicate that p53-independent apoptosis caused by MAGE-A4⌬N1 is mediated via a mitochondrial pathway.
Interaction of MAGE-A4⌬N1 with Miz-1 Resulting in Suppression of the p21
Cip1 Expression-To further characterize the pro-apoptotic activity of MAGE-A4⌬N1, we performed a yeast two-hybrid assay using MAGE-A4⌬N1 as bait. We identified 10 clones of 3.5 ϫ 10 6 yeast clones transformed with a human U-2 OS cell cDNA library. Each clone proliferated on media containing the histidine inhibitor 3AT and was positive for ␤-galactosidase staining (Fig. 5A and data not shown) . DNA sequencing of the rescued plasmids revealed that two clones encoded the C-terminal 391 amino acids of Miz-1.
To confirm that MAGE-A4⌬N1 interacts with Miz-1 in mammalian cells, COS-7 cells were co-transfected with plasmids expressing HA-tagged human full-length Miz-1 and FLAGtagged MAGE-A4⌬N1. When cell lysates were immunoprecipitated with an anti-FLAG antibody, HA-Miz-1 was detected in the precipitates but not in those from cells co-transfected with the parental FLAG vector and HA-Miz-1 (Fig. 5B, left panels) . Reciprocally, MAGE-A4⌬N1 was detected in the anti-HA immunoprecipitates from cells co-transfected with plasmid expressing HA-Miz-1 and FLAG-MAGE-A4⌬N1 (Fig. 5B , right C, effects on the protein levels of Bcl-2 family members. U-2 OS cells were transfected with plasmids expressing MAGE-A4⌬N1 (⌬N1) or vector alone (mock). 48 h after transfection, expressions of Bcl-2 family members and ␤-actin were analyzed by Western blotting. D, effects on the p53 protein level. U-2 OS cells were transfected with plasmids expressing indicated proteins or vector alone (mock). Plasmids expressing luciferase were co-transfected to control transfection efficiency. 48 h after transfection, the expressions of p53, luciferase and ␤-actin were analyzed by Western blotting. E, effects on expression of p21
Cip1 . HeLa cells were transfected with plasmids expressing indicated proteins, and p21 Cip1 and ␤-actin expressions were analyzed by Northern (left panels) and Western (right panels) blots using cDNA probes and antibodies as indicated. panels). Furthermore, in the HeLa cells expressing FLAG-MAGE-A4⌬N1 and HA-Miz-1, double immunofluorescence staining showed that expression of MAGE-A4⌬N1 did not affect the localization of Miz-1 and that both proteins were colocalized in the nucleus (Fig. 5C ). In contrast, FLAG-tagged full-length MAGE-A4 localized mainly in the cytoplasm (Fig.  5D) . We next examined the interaction between MAGE-A4⌬N1 and endogenous Miz-1 in HeLa cells. As shown in Fig. 5E , the endogenous Miz-1 was co-immunoprecipitated with MAGE-A4⌬N1 protein.
Miz-1 binds to the proximal promoter region of the p21
Cip1
gene, and together with p53 enhances its transcription. As shown in Fig. 5F , expression of the p21 Cip1 transcript was decreased by expression of MAGE-A4⌬N1, and was relieved by overexpression of Miz-1. To determine the underlying mechanisms of the MAGE-A4⌬N1-induced decrease in p21
Cip1 expression, an electrophoretic mobility shift assay was performed. COS-7 cells were transfected with plasmids expressing HA-tagged Miz-1, and nuclear extracts analyzed. As shown in Fig. 5G , HA-Miz-1 bound to the proximal promoter sequence of p21
. When FLAG-tagged MAGE-A4⌬N1 was co-expressed, the band intensity was not affected. The band intensity was decreased by antibodies against FLAG and HA, indicating that the band contains a complex of MAGE-A4⌬N1 and Miz-1. We found that MAGE-A4⌬N1 suppressed the promoter activity of the p21
Cip1 gene in HeLa cells in a dose-dependent manner (Fig. 5H) . These results suggest that MAGE-A4⌬N1 does not affect the binding of Miz-1 to the proximal promoter region of p21
, but inhibits the transactivating activity of Miz-1 on p21
Cip1 expression, followed by induction of p53-dependent apoptosis.
Processing of MAGE-A4 Generates a C-terminal Fragment Similar to MAGE-A4⌬N1-As the N-terminally truncated
MAGE-A4 mutants showed pro-apoptotic activity that was absent in full-length MAGE-A4, we suspected that processing of the latter occurs in human cells to generate a C-terminal fragment capable of inducing apoptosis. To investigate this possibility, full-length MAGE-A4 was tagged with FLAG at its C terminus and expressed in 293T cells. As shown in Fig. 6A , full-length MAGE-A4 generated a fragment, the mobility of which was between those of MAGE-A4⌬N1 (107 amino acids) and MAGE-A4⌬N2 (91 amino acids). When the N terminus of MAGE-A4 was tagged with FLAG, no fragment was detected, indicating that the truncated protein was a C-terminal fragment. Since both MAGE-A4⌬N1 and MAGE-A4⌬N2 had proapoptotic activities (Fig. 2B) , this C-terminal fragment most probably has a pro-apoptotic activity as well.
We next investigated whether caspases are involved in the processing. As shown in Fig. 6B , the processing of MAGE-A4 was completely abrogated by the broad-range caspase inhibitor Z-VAD-FMK, indicating possible caspase-dependence. However, the processing was not blocked by the caspase-2 inhibitor Ac-LDESD-CHO, the caspase-3 inhibitor Z-SEVD-FMK or the caspase-9 inhibitor Z-LEHD-FMK (Fig. 6B) . Because there is no caspase-cleavable consensus amino acid motif in the MAGE-A4 sequence, we investigated the possibility that an unknown caspase cleaves MAGE-A4. Since aspartatic acid (D)
FIG. 5. Identification of Miz-1 as a MAGE-A4⌬N1-binding protein and suppression of p21
Cip1 expression. A, interaction in yeasts. Yeast cells were co-transformed with the human MAGE-A4⌬N1 (⌬N1) cDNA, MAGE-A4⌬C1 (⌬C1) cDNA or none (Gal4-BD) in pAS2-1 vector in combination with the isolated partial Miz-1 cDNA or none (Gal4-AD) in pACT2 vector as indicated. Yeast were then plated onto media lacking tryptophan and leucine (S.D./-W-L) and media lacking tryptophan, leucine, and histidine and supplemented with 3AT (S.D./-W-L-Hϩ3AT). B, interaction of full-length Miz-1 and MAGE-A4⌬N1. COS-7 cell lysates were prepared after co-transfection with vectors expressing HA-tagged Miz-1, HA alone, FLAG-tagged MAGE-A4⌬N1 (FLAG-⌬N1), and FLAG alone as indicated. The lysates and those immunoprecipitated with antibodies against FLAG or HA were analyzed by Western blotting using the indicated antibodies. C, co-localization of MAGE-A4⌬N1 and Miz-1. HeLa cells co-transfected with plasmids expressing HA-Miz-1 and FLAG-MAGE-A4⌬N1 were incubated with rabbit anti-HA and mouse anti-FLAG antibodies, visualized with TRITC-linked anti-rabbit and FITC-linked anti-mouse IgGs, and observed under confocal microscope. DNA was stained with DAPI. D, localization of full-length MAGE-A4 and Miz-1. HeLa cells were co-transfected with plasmids expressing HA-Miz-1 and FLAG-MAGE-A4 and analyzed as in C. E, interaction of MAGE-A4⌬N1 with endogenous Miz-1. HeLa cells were transfected with plasmids expressing FLAG-tagged MAGE-A4⌬N1 (ϩ) or vector alone (Ϫ). Lysates (lower panel) and those immunoprecipitated with anti-FLAG antibody (upper panel) were analyzed by Western blotting using anti-Miz-1 antibody. F, suppression of Miz-1-induced p21
Cip1 expression by MAGE-A4⌬N1. HeLa cells were transfected with plasmids expressing HA-tagged Miz-1 and FLAG-tagged MAGE-A4⌬N1 as indicated, and p21
Cip1 and ␤-actin expression were analyzed by Northern blotting. G, gel-shift assays demonstrating binding of MAGE-A4⌬N1 and Miz-1 to the proximal promoter sequence of p21
Cip1
. COS-7 cells were transfected as in F. Nuclear extracts were analyzed by gel shift assay using the indicated antibodies. Arrowhead designates the specifically bound complexes as judged by competition with cold competitors. H, reporter assays demonstrating dose-dependent down-regulation of the promoter activity of p21
Cip1 gene by MAGE-A4⌬N1. HeLa cells were transfected with plasmids expressing MAGE-A4⌬N1 and empty vectors as indicated together with the reporter plasmid. Luciferase activities were determined 30 h after transfection. *, p Ͻ 0.05 versus vector alone is usually critical for cleavage by caspases, we introduced point mutations to substitute alanine (A) for aspartatic acid (D) at positions 215 and 233 of MAGE-A4 (D215A and D233A, respectively) (Fig. 6C) . The processed fragment was still generated in 293T transfectants overexpressing these mutant proteins (data not shown), suggesting that caspases are not directly involved in the processing of MAGE-A4.
To determine the cleavage site, we compared the mobilities of various mutant MAGE-A4 proteins with that of the processed form (Fig. 6D) . The mobility of the mutant containing amino acid residues 215-317 of MAGE-A4 with an additional methionine at the N terminus (Met-215) was similar to that of the cleaved C-terminal fragment of the wild-type MAGE-A4 (FL). When methionine was added to the C terminus of the wild-type MAGE-A4 (FL-M), the mobility of the cleaved fragment became equal to that of the mutant containing amino acid residues 214 -317 of MAGE-A4 with an additional methionine (Met-214). When a single point mutation was introduced at position 213 of MAGE-A4 (E213A), the band corresponding to the cleaved C-terminal fragment of the wild-type MAGE-A4 was not observed (data not shown). These findings indicate that the cleavage site is between amino acid residues 213 (Glu) and 214 (Gly), generating a C-terminal fragment of 104 amino acids in length. This fragment showed pro-apoptotic activity and increased the p53 protein level as efficiently as MAGE-A4⌬N1 as expected (data not shown).
DNA-damaging agents induce cleavage of hRad21 to generate a C-terminal fragment with pro-apoptotic activity (32) . Similarly, adriamycin increased the ratio of the processed fragment to full-length MAGE-A4 protein in 293T cells (Fig. 6E) . At the dose of adriamycin employed, no apoptosis was observed in 293T cells not expressing MAGE-A4 (Fig. 6F) . Expression of MAGE-A4 protein alone did not induce apoptosis. When combined, however, pro-apoptotic activity of MAGE-A4 was observed (Fig. 6F) . These findings suggest that processing of MAGE-A4 is induced by adriamycin resulting in the genertion of the C-terminal fragment with pro-apoptotic activity.
Suppressive Effect of Tat-MAGE-A4⌬N1 Fusion Protein on Cell Growth-We next assessed the possibility that MAGE-A4⌬N1 may be exploited as a chemotherapeutic agent against HCCs. The HIV Tat protein can traverse biological membranes efficiently (33) . To introduce MAGE-A4 and its mutant proteins into cells, we made the Tat fusion proteins, Tat-MAGE-A4, Tat-MAGE-A4⌬C1, and Tat-MAGE-A4⌬N1 (Fig. 7A) . Western blot analysis revealed that Tat-MAGE-A4 entered cells and progressively accumulated in the nucleus as well as the cytoplasm (Fig. 7B) . Possible cytoplasmic contamination was excluded by the absence of ␣-tubulin in the nuclear extracts.
Consistent with the results obtained by DNA transfection experiments (Fig. 3D) , Tat-MAGE-A4⌬N1 increased the p53 protein level in GK-S25 cells and HuH-7 hepatoma cells (Fig.  7C and data not shown) . Tat-MAGE-A4⌬N1, but not Tat-MAGE-A4, reduced the cellular growth rate in a dose-dependent manner (Fig. 7D and data not shown) .
by Western blotting using anti-FLAG antibody. Arrowheads indicate the mobilities of the cleaved C-terminal fragments. E, increased processing induced by a DNA-damaging agent. 293T cells were transfected with FL-FLAG and cultured in the presence of adriamycin (Ad) at indicated doses. 18 h after transfection, cell lysates were analyzed as in A. Arrow and arrowhead indicate the mobility of MAGE-A4 and the C-terminal fragment, respectively. MAGE-A4 is cleaved by a caspasedependent protease activity, especially when exposed to genotoxic stress, to generate MAGE-A4⌬N1 (⌬N1), which inhibits p21
Cip1 transcription by binding to Miz-1 and increases the p53 protein level leading to induction of pro-apoptotic genes. In addition, MAGE-A4⌬N1 decreases the Bcl-xL protein level. All of these effects contribute to cell death. pressor protein p53, and promote cell cycle arrest to enable DNA repair or apoptosis to eliminate defective cells (9, 19, 34) . The cytostatic effect of p53 is mainly mediated by p21 Cip1 up-regulation, whereas the apoptotic effect is mediated by transcriptional activation of pro-apoptotic genes such as Puma and Noxa, transcriptional repression of Bcl-2 and IAPs, or transcription-independent mechanisms (9, 35, 36) . Recently, Myc has been shown to determine whether cytostasis or apoptosis takes place (21, 37) . Myc is directly recruited to the p21
promoter by binding to Miz-1, which blocks p21
Cip1 transcription induced by p53. As p21
Cip1 has an anti-apoptotic activity as well, this switches the response to DNA damage from cytostatic to apoptotic. The present study demonstrated that the C-terminal fragment of MAGE-A4 (MAGE-A4⌬N1) binds to Miz-1 and is recruited to the p21
Cip1 promoter, resulting in inhibition of p21
Cip1 expression and sensitization of cells to p53-dependent apoptosis. The relationship between Myc and MAGE-A4⌬N1 remains to be clarified.
In response to ionizing radiation, the kinase ATM activates the downstream kinase Chk2/hCds1, which stabilizes p53 at least in part by direct phosphorylation (38) . In hypoxic conditions, Mdm2 is down-regulated, resulting in an inhibition of p53 export from the nucleus to the cytoplasm for degradation (39) . We found that MAGE-A4⌬N1 increased the p53 protein level and induced apoptosis. Gankyrin interacts with MAGE-A4 through a C-terminal region containing MAGE-A4⌬N1 (22) . However, the finding that MAGE-A4⌬N1⌬C2 and MAGE-A4⌬N1⌬C3 that do not bind to gankyrin induced p53-up-regulation, while MAGE-A4 and MAGE-A4⌬N2 that bind to gankyrin did not (Fig. 3C) argues against a notion that p53-up-regulation is mediated by binding to gankyrin. Further identification of molecule(s) that interacts with MAGE-A4⌬N1 will facilitate our understanding of the molecular mechanisms underlying the observed p53-up-regulation.
Currently, mitochondria are thought to be a central regulatory element in stress-induced apoptosis (26, 28) . Cytotoxic stress activates caspases by initiating signaling pathways that converge on the Bcl-2 family of proteins (27, 40) . The Bcl-2 family contains both pro-and anti-apoptotic members. A balance between members of this family is thought to determine whether mitochondria remain intact or become permeabilized and release proteins that promote cell death, such as cytochrome c. Cytochrome c activates caspase-9, which, in turn, activates caspase-3 (26, 28, 41) . Here we demonstrated that MAGE-A4⌬N1 induces changes in mitochondrial integrity, followed by caspase-9 activation in a p53-independent manner. We also demonstrated that MAGE-A4⌬N1 decreases the expression of Bcl-xL, an anti-apoptotic member of the Bcl-2 family. As Bcl-xL antisense oligonucleotides enhance the effect of chemotherapy in a variety of tumor cells and Bcl-xL is highly expressed in HCCs (42, 43) , MAGE-A4⌬N1 might sensitize HCC cells to chemotherapeutic agents as well as induce apoptosis.
The caspase family of cysteine proteases is activated and cleaves many proteins during apoptosis (44) . Although caspases show high cleavage specificity for certain amino acid motifs containing an aspartic acid (44) , recent studies have demonstrated that some caspases can cleave proteins without known caspase-cleavage sites (41, 44) . In the present study, generation of the C-terminal fragment of MAGE-A4 was inhibited by a broad-range caspase inhibitor, but it was not inhibited by site-directed mutagenesis at aspartic acids. The site of cleavage was between amino acid residues 211 (Glu) and 236 (Gly). These findings suggest that the caspase cleaves MAGE-A4 at a previously unreported site or the protease responsible for the cleavage is not a caspase but sensitive to the broad-range caspase inhibitor. Alternatively, the caspase activates a downstream non-caspase protease, which subsequently cleaves MAGE-A4. The latter possibility is not without precedent. The calpain inhibitor calpastatin is sensitive to caspase proteolysis during early apoptosis, and degradation of calpastatin results in activation of calpain (46) . Activated calpain subsequently truncates many cellular proteins involved in apoptosis (41, 47) . Recently, we have found that the cleavage of MAGE-A4 is inhibited in the presence of the proteasome inhibitors.
2 Although the identity of the protease and its relationship to the 26 S proteasome remain to be elucidated, generation of the MAGE-A4 C-terminal fragment was increased by adriamycin, which suggests that the protease is activated by genotoxic stress. Thus, MAGE-A4 may be involved in genotoxic stress response by affecting the protein levels of p53 and p21
Cip1 . Recently, several proteins with protein transduction domains such as Tat protein have been shown to traverse biological membranes efficiently (33) . We showed that the Tat-MAGE-A4⌬N1 fusion protein suppresses gankyrin-induced tumorigenesis in vivo. Since uptake of the Tat fusion protein was rapid (Fig. 7B ) and the pretreated tumor cells were washed before injection, the effect of Tat-MAGE-A4⌬N1A is most probably directly on the tumor cells rather than a peripheral effect at the site of injection, e.g. on angiogenesis. Within the tumor cells, Tat-MAGE-A4⌬N1A increases the p53 protein level, binds to Miz-1, and induces apoptosis. A current model of the MAGE-A4⌬N1-induced apoptotic pathway is shown in Fig. 8 . Further clarification of the mechanisms underlying the antitumorigenic and pro-apoptotic activities of MAGE-A4⌬N1 will facilitate development of novel therapeutics against HCCs, and also shed light on physiological function of MAGE-A proteins.
